Tyverb
Two-drug combo shown to significantly shrink breast cancer in days
March 10, 2016Medical Communications, Research and Development GSK, Herceptin, Novartis, Roche, Tyverb
Results of a clinical trial have revealed that Novartis’ Tyverb (lapatinib), in combination with Roche’s Herceptin (trastuzumab), can significantly shrink …
GSK and Roche get EU breast cancer indication
August 15, 2013Sales and Marketing GSK, Herceptin, Roche, Tyverb, Xeloda, breast cancer
The European Commission has granted a new indication for the use of GSK’s breast cancer drug Tyverb in combination with …
GSK loses Tyverb patent
August 6, 2013Sales and Marketing Cancer, GSK, GlaxoSmithKline, Tyverb
GlaxoSmithKline has received a knockback from authorities in India, who have revoked the patent on its breast cancer drug Tyverb. …
GSK pulls Tyverb extension in Europe
February 17, 2012Sales and Marketing GSK, Herceptin, Tyverb, Xeloda
GlaxoSmithKline has withdrawn its European application to extend the licence of its breast cancer pill Tyverb. The firm was seeking …
NICE cannot recommend breast cancer drugs
February 14, 2012Sales and Marketing GSK, Herceptin, NHS, NICE, Roche, Tyverb
NICE is not recommending GlaxoSmithKline’s Tyverb or Roche’s Herceptin for use in certain breast cancer patients. The watchdog said in …
GSK’s Tyverb fails late-stage trial in breast cancer
December 12, 2011Research and Development, Sales and Marketing GSK, Tyverb, breast cancer
GlaxoSmithKline’s Tyverb has failed to help women with HER2 positive breast cancer increase their survival. The TEACH study’s primary objective …
GSK scales back breast cancer trial
September 12, 2011Research and Development, Sales and Marketing GSK, Tyverb
GSK has halted one of the four phase III studies that make up the ALTTO programme for its cancer drug …
GlaxoSmithKline to drop Alli and other OTC products
April 15, 2011Research and Development, Sales and Marketing Alli, GSK, OTC, Tyverb
GlaxoSmithKline is to sell off its weight loss drug Alli and other less profitable non-prescription drugs. GSK announced its decision …
NICE rejects GSK Tyverb appeal
October 14, 2010Sales and Marketing GlaxoSmithKline, NICE, Tyverb
NICE’s independent appeal board has ruled the UK drug’s watchdog did not exceed its powers when issuing guidance on GlaxoSmithKline’s …
NICE says no to GSK breast cancer drug
June 10, 2010Sales and Marketing NICE, Tyverb
NICE has issued final draft guidance restricting use of GlaxoSmithKline’s breast cancer drug Tyverb to clinical trials, citing high cost …
Sanofi’s Humenza poised to be Europe’s fifth swine flu vaccine
February 22, 2010Sales and Marketing Sanofi Pasteur, Tyverb, Zeftera, swine flu
Sanofi Pasteur’s Humenza is set to become the fifth swine flu vaccine in Europe after gaining the support of a …
NICE to reconsider GSK’s Tyverb
July 9, 2009Research and Development, Sales and Marketing GSK, NICE, Tyverb
NICE is to reconsider Tyverb under its new lenient approach for end-of-life drugs, after GSK appealed its previous rejection of …
NICE rejects Tyverb despite price offer
March 5, 2009Research and Development NICE, Tyverb
NICE has rejected GSK's breast cancer drug Tyverb, despite an offer from the company to cut the cost of treatment. …
